FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080821075> ?p ?o ?g. }

• W3080821075 abstract "Abstract Objectives The aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia. Trial design Multicentre, randomized clinical trial, controlled, open label, parallel group, to evaluate the effectiveness and safety of high dose dexamethasone in adult patients with confirmed COVID-19, with Acute Respiratory Distress Syndrome. Participants We will include patients with SARS-Cov-2 pneumonia who develop acute respiratory distress syndrome, in several intensive care units (ICU) in Buenos Aires, Argentina (CEMIC, Clinica Bazterrica, Sanatorio Sagrado Corazon) Inclusion criteria: Men and women, age ≥ 18 years old. Confirmed diagnosis of SARS-CoV-2 infection, by RT-PCR. Diagnosis of Acute Respiratory Distress Syndrome (hypoxemic respiratory failure not explained by cardiac disease + PaO 2 /FiO 2 ratio < 300 with a Positive End-Expiratory Pressure ≥ 5 cm H 2 O + bilateral pulmonary infiltrates) Length of mechanical ventilation of at least 72 hours Informed consent (next of kin / legal guardian) Exclusion criteria: Pregnant or breast-feeding women. Terminal disease (advanced cancer; under palliative care; cardiovascular, respiratory, or renal disease with a life expectancy less ≤ 1 year). Therapeutic limitation (advance directives or do not resuscitate order) Severe immunosuppression (HIV infection, long-term use of immunosuppressive agents, active cancer). Patients under chronic treatment with glucocorticoids for other diseases (≥ 8 mg prednisone, or equivalent) Participation in another randomized clinical trial. Intervention and comparator Eligible patients will be randomized to receive standard ICU patient care (group 1) or standard ICU patient care plus high dose dexamethasone (group 2). Group 1: dexamethasone up to 6 mg/24 hours for up to 10 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines. Group 2: dexamethasone 16 mg/24 hours for 5 days followed by dexamethasone 8 mg/24 hours for 5 days + ventilatory, hemodynamic, nutritional, and antimicrobial support according to international guidelines. Main outcome The main result is ventilator-free days at 28 days (Days without ventilator support in the first 28 days following randomization). Secondary outcomes are 28-days and 90-days mortality, frequency of nosocomial infections in the first 28 days after randomization, Sequential Organ Failure Assessment (SOFA) score variation and prone position in the first 10-days, viral shedding 28-days after randomization, and delirium and muscle weakness at ICU discharge. Randomisation Treatment will be assigned according to site stratified randomization by permuted random blocks sequence 1:1 generated with a table in R language concealed in a randomization tool in REDCap (Research Electronic Data CAPture) platform. Blinding (masking) This is an open trial, so no masking of treatment assignment will be used. Numbers to be randomised (sample size) Assuming a 3 days difference in ventilator-free days between treatment groups, with a mean of 9 days, and a standard deviation of 9 days; the necessary sample size would be 284 subjects (142 per group), with a power of 80% and a two-tailed alpha error of 0.05. Trial Status The protocol with code 1264, version 3.0 on date: May 13, 2020 is approved by the local Ethics Committee. The trial is in the recruitment phase. Recruitment began May 22, 2020 and is anticipated to be complete by the end of December 2021. Trial registration The trial was registered under the title “Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial” with ClinicalTrials number NCT04395105, https://clinicaltrials.gov/ct2/show/NCT04395105 , registered on 20 May 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol." @default.
• W3080821075 created "2020-09-01" @default.
• W3080821075 creator A5010648951 @default.
• W3080821075 creator A5014190806 @default.
• W3080821075 creator A5018043232 @default.
• W3080821075 creator A5032605840 @default.
• W3080821075 creator A5047328023 @default.
• W3080821075 creator A5062682690 @default.
• W3080821075 creator A5077129128 @default.
• W3080821075 creator A5089254224 @default.
• W3080821075 date "2020-08-26" @default.
• W3080821075 modified "2023-10-17" @default.
• W3080821075 title "High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial" @default.
• W3080821075 doi "https://doi.org/10.1186/s13063-020-04646-y" @default.
• W3080821075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7447582" @default.
• W3080821075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32843098" @default.
• W3080821075 hasPublicationYear "2020" @default.
• W3080821075 type Work @default.
• W3080821075 sameAs 3080821075 @default.
• W3080821075 citedByCount "23" @default.
• W3080821075 countsByYear W30808210752020 @default.
• W3080821075 countsByYear W30808210752021 @default.
• W3080821075 countsByYear W30808210752022 @default.
• W3080821075 countsByYear W30808210752023 @default.
• W3080821075 crossrefType "journal-article" @default.
• W3080821075 hasAuthorship W3080821075A5010648951 @default.
• W3080821075 hasAuthorship W3080821075A5014190806 @default.
• W3080821075 hasAuthorship W3080821075A5018043232 @default.
• W3080821075 hasAuthorship W3080821075A5032605840 @default.
• W3080821075 hasAuthorship W3080821075A5047328023 @default.
• W3080821075 hasAuthorship W3080821075A5062682690 @default.
• W3080821075 hasAuthorship W3080821075A5077129128 @default.
• W3080821075 hasAuthorship W3080821075A5089254224 @default.
• W3080821075 hasBestOaLocation W30808210751 @default.
• W3080821075 hasConcept C126322002 @default.
• W3080821075 hasConcept C141071460 @default.
• W3080821075 hasConcept C141983124 @default.
• W3080821075 hasConcept C159110408 @default.
• W3080821075 hasConcept C168563851 @default.
• W3080821075 hasConcept C177713679 @default.
• W3080821075 hasConcept C187212893 @default.
• W3080821075 hasConcept C2777914695 @default.
• W3080821075 hasConcept C2987404301 @default.
• W3080821075 hasConcept C2994186709 @default.
• W3080821075 hasConcept C71924100 @default.
• W3080821075 hasConceptScore W3080821075C126322002 @default.
• W3080821075 hasConceptScore W3080821075C141071460 @default.
• W3080821075 hasConceptScore W3080821075C141983124 @default.
• W3080821075 hasConceptScore W3080821075C159110408 @default.
• W3080821075 hasConceptScore W3080821075C168563851 @default.
• W3080821075 hasConceptScore W3080821075C177713679 @default.
• W3080821075 hasConceptScore W3080821075C187212893 @default.
• W3080821075 hasConceptScore W3080821075C2777914695 @default.
• W3080821075 hasConceptScore W3080821075C2987404301 @default.
• W3080821075 hasConceptScore W3080821075C2994186709 @default.
• W3080821075 hasConceptScore W3080821075C71924100 @default.
• W3080821075 hasIssue "1" @default.
• W3080821075 hasLocation W30808210751 @default.
• W3080821075 hasLocation W30808210752 @default.
• W3080821075 hasLocation W30808210753 @default.
• W3080821075 hasLocation W30808210754 @default.
• W3080821075 hasOpenAccess W3080821075 @default.
• W3080821075 hasPrimaryLocation W30808210751 @default.
• W3080821075 hasRelatedWork W2111407718 @default.
• W3080821075 hasRelatedWork W2252881016 @default.
• W3080821075 hasRelatedWork W2340243368 @default.
• W3080821075 hasRelatedWork W2410854040 @default.
• W3080821075 hasRelatedWork W2415186040 @default.
• W3080821075 hasRelatedWork W2437675444 @default.
• W3080821075 hasRelatedWork W3040254066 @default.
• W3080821075 hasRelatedWork W3202490215 @default.
• W3080821075 hasRelatedWork W4256514411 @default.
• W3080821075 hasRelatedWork W4381956847 @default.
• W3080821075 hasVolume "21" @default.
• W3080821075 isParatext "false" @default.
• W3080821075 isRetracted "false" @default.
• W3080821075 magId "3080821075" @default.
• W3080821075 workType "article" @default.